Because progressive forms of MS, such as SPMS, lead to increased disability over time, they are often associated with lower quality of life and an increase in complications that may affect life span.

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Genentech, the drug's manufacturer ...